FHD-286 is the first dual inhibitor of SMARCA2/SMARCA4. , can be used for metastatic melanoma and advanced hematological tumor research.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||＞10 μM for FaSSIF|
|Related Epigenetic Reader Domain Products|
Mi-3 (Menin-mLL inhibitor 3) is an effective and high affinity menin-MLL inhibitor with IC50 value of 648 nM and Kd value of 201 nM.
Alobresib (GS-5829) is a BET bromine domain inhibitor that can be used in the study of recurrent and drug-resistant overexpressed c-Myc uterine serous carcinoma.
ZL0420 is a potent and selective BET bromine domain 4 (BRD4) inhibitor of BRD4 BD1 and BRD4 BD2 IC50 27 nM and 32 nM, respectively.
MS645 is a BET bromodomains (BrD) inhibitor for K of BRD4-BD1/BD2i The value is 18.4 nM. MS645 spatially limits the divalent inhibition of BRD4 BrDs, resulting in sustained inhibition of BRD4 transcriptional activity in solid tumor cells.
LT052 is a highly selective BET BD1 inhibitor IC50 87.7 nM. LT052 exhibits nanomolar-grade inhibitory activity of BRD4 BD1 and is 138 times more selective than BRD4 BD2 (IC).50=12.130 μM)。 LT052 has anti-inflammatory activity and can be used in acute gouty arthritis studies.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.